If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

The US Food and Drug Administration (FDA) has approved a non-opioid drug for severe post-surgical pain, which could “redefine ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

RBC Capital Markets analyst Bish Koziol made eight changes to his quantitatively driven top 40 list of stock picks. Maple ...

AbbVie, Danaher, Vertex Pharmaceuticals, Cencora, GSK, Thermo Fisher Scientific, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks ...

In its latest move, Google has made Gemini 2.0, its most powerful suite of AI models, available to the general public.

For those seeking a cost-effective solution without compromising quality, Google unveiled Gemini 2.0 Flash-Lite in public ...

The cost-efficient model dubbed Gemini 2.0 Flash-Lite comes as a successor to the Gemini 1.5 Flash while sticking to the same ...

The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...

Google has made Gemini 2.0 "generally available" through the Gemini API in Google AI Studio and Vertex AI, marking a ...

Willis Investment Counsel grew its holdings in shares of Exxon Mobil Co. (NYSE:XOM – Free Report) by 0.9% during the fourth ...

The Alphabet giant has expanded its Gemini AI lineup with the affordable "Gemini-Lite" model, aiming to compete with low-cost ...